Highlights Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:59:52 2026-08-21 EDT			5-day change	1st Jan Change
3.305 ^USD	+2.96%		+3.28%	+20.18%

08-19	BMO Capital Initiates Perspective Therapeutics at Outperform	MT
08-14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT

Highlights

08-10	Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
07-17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI
06-03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI
05-18	Perspective Therapeutics, Inc. Announces First Patients Dosed In New Cohorts Of Ongoing Phase 1/2a Studies	CI
05-11	Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Perspective Therapeutics Inc Presents Updated Interim Data of [212Pb]VMT-a-NET in Ongoing Phase 1/2A Clinical Trial	CI
03-16	Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-12	Perspective Therapeutics, Inc. Provides Clinical Updates	CI
01-09	Perspective Therapeutics, Inc. Announces Updated Interim Results from Its Ongoing Phase 1/2A Clinical Trial	CI
12-04	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation At the Asco Gastrointestinal Cancers Symposium	CI
11-10	Perspective Therapeutics Q3 net loss widens to $26 mln	RE
11-10	Perspective Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-20	Perspective Therapeutics, Inc. Announces Updated Interim Data from Its Ongoing Phase 1/2A Clinical Trial Of212pb)Vmt-Net At the Esmo Congress 2025	CI
25-10-02	Perspective Therapeutics, Inc. Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-A Positive Solid Tumors	CI
25-09-15	Perspective Therapeutics, Inc. Progresses Dose Finding for [212Pb)VMT01 in Combination with Nivolumab in Its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma	CI
25-08-13	Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-24	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ESMO Congress 2025	CI
25-06-21	Perspective Therapeutics, Inc. Commences Recruitment for VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial	CI
25-05-30	Perspective Therapeutics, Inc. Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual Meeting	CI
25-05-12	Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-29	Perspective Therapeutics, Inc. Announces First Patient Dosed with Psv359 in A Phase 1/2A Study in Patients with Fap-A Positive Solid Tumors	CI
25-04-11	Perspective Therapeutics, Inc. Announces First Patient Dosed with212Pb)VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma	CI
25-03-26	Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-17	Perspective Therapeutics, Inc. Announces First Patient Dosed with Cm1R-Positive Metastatic Melanoma	CI